PDE4D inhibitor 1
PDE4-IN-1 is a PDE4 inhibitor with high potency (IC50 : 8.6 nM) and selectivity over other PDE subtypes. PDE4-IN-1 inhibits the release of inflammatory cytokines and chemokines. PDE4-IN-1 greatly restores impaired cAMP-CREB signaling pathway. PDE4-IN-1 inhibits proliferation and promotes differentiation to reverse the formation of psoriasis.
For research use only. We do not sell to patients.
- Formula: C25H25F2NO7
- Molecular Weight:489.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PDE4B1 5.3 nM (IC50) |
PDE4D2 8.6 nM (IC50) |
PDE4A10 100 nM (IC50) |
PDE4C1 747 nM (IC50) |
PDE5A1 1730 nM (IC50) |
PDE10A2 1953 nM (IC50) |
PDE7A1 5913 nM (IC50) |
PDE1B2 >10000 nM (IC50) |
PDE2A >10000 nM (IC50) |
PDE3A >10000 nM (IC50) |
PDE8A1 >10000 nM (IC50) |
PDE9A2 >10000 nM (IC50) |
In Vitro
PDE4-IN-1 (Compound L30) (5-20 μM, 2 h) reduces the mRNA levels of the inflammatory cytokines (IL-1β , IL-6, and TNF-α) in LPS-induced Raw264.7 cells[1].
PDE4-IN-1 (5-20 μM, 24 h) reduces the mRNA levels of the inflammatory cytokines (CXCL-2, IL-17, and TNF-α) in M5-stimulated HaCaT cells[1].
PDE4-IN-1 (0-20 μM, 24 h) inhibits the proliferation of M5-stimulated HaCaT cells[1].
PDE4-IN-1 (20 μM, 24 h) decreases the protein expressions of K6 and K17 whilst upregulating the expression of differentiation protein (K1 and K10) in M5-stimulated HaCaT cells[1].
PDE4-IN-1 (20 μM, 2 h) with Roflumilast (HY-15455) restores cAMP levels and enhances phosphorylation of downstream CREB in M5-stimulated HaCaT cells[1].
PDE4-IN-1 (0-80 μM, 24 h) shows low cytotoxicities for RAW264.7 and HaCaT cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice models (6-8 weeks old, weighing 20-22 g each, a total of 40 mice) with 5% IMQ-containing cream for 7 days [1]
-
Dosage:0.3% ointment-100 mg
-
Administration:Topical administrations
-
Result:Alleviated psoriatic symptoms and was more potent to decrease the thickness, scales, and erythema scores than Roflumilast (20 mg/kg) in the last 4 days.
Downregulated inflammatory cytokines and chemotaxis such as TNF-α, IL-1β, IL-6, IL-17, CXCL-2, and CCL-20.
Reduced protein expression of K6 and K17.
Reversed expression level of K1 and K10.
Exerted antipsoriasis effects by inhibiting the excessive proliferation and promoting poor differentiation.
Partly reversed the body weight loss and reduced skin thickness induced by IMQ suggesting low risk of toxicity in vivo.
Chemical Information
-
Molecular Weight 489.47
-
Formula C25H25F2NO7
-
SMILES
COC([C@H]1C[C@@H](OC2=C3OC(C4=CC=C(OC(F)F)C(OCC5CC5)=C4)=CC3=CC=C2O)CN1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)